Market Overview

KeyBanc: Veeva Systems Is A Core Holding In The Cloud Space

Share:
KeyBanc: Veeva Systems Is A Core Holding In The Cloud Space
Related VEEV
Veeva Systems Q4 Earnings Preview
Vetr Crowd Downgrades Veeva Systems
Didn't Buy The Breakout? Veeva Taught It May Not Be Too Late (Investor's Business Daily)

Veeva Systems Inc (NYSE: VEEV) reported third-quarter results Tuesday that included a top- and bottom-line beat and encouraging guidance for the coming fiscal quarter and next year.

The Analyst

KeyBanc Capital Markets' Brent Bracelin maintains an Overweight rating on Veeva Systems' stock with an unchanged $70 price target.

The Thesis

Veeva's earnings report was highlighted by 23-percent revenue growth from a year ago, while Vault revenue rose 50 percent over the same time period, Bracelin said in a research report. (See Bracelin's track record here.) 

Vault remains the "primary growth engine" and contributes to the company's investment profile as a core cloud holding stock that can justify a premium valuation, the analyst said. 

Bracelin said other notable aspects of Veeva's earnings report include: 

A major contract win with a top-20 pharmaceutical firm in Japan that could potentially open the door for more opportunities in the country. 

A sequential improvement in operating margin to 32.7 percent.

Free cash flow per share of 24 percent that outpaced revenue growth.

Veeva showed that its QualityOne opportunity has "untapped" potential, and incremental clinical expansion could help sustain subscription revenue growth above 20 percent on top of its already best-in-class operating margin of more than 30 percent.

Price Action

Shares of Veeva were trading lower by nearly 5 percent ahead of Wednesday's market open after gaining more than 40 percent since the start of 2017.

Related Links:

Veeva Systems Delivers In Q2, So Why Did Shares Drop?

Veeva Systems Q2 Beat And Raise Not Good Enough

Latest Ratings for VEEV

DateFirmActionFromTo
Mar 2018JMP SecuritiesMaintainsMarket OutperformMarket Outperform
Mar 2018JP MorganDowngradesOverweightNeutral
Mar 2018KeyBancMaintainsOverweightOverweight

View More Analyst Ratings for VEEV
View the Latest Analyst Ratings

Posted-In: Brent Bracelin Japan KeyBanc Capital Markets pharmaceuticalsAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (VEEV)

View Comments and Join the Discussion!